Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risvodetinib Phase 1 in Healthy Elderly and Parkinson's
NCT04350177Phase 1Completed
- Sponsor
- ABLi Therapeutics, Inc.
- Start
- Feb 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of risvodetinib in Parkinson's disease (PD) (3 arms), sponsored by ABLi Therapeutics, Inc. Primary endpoints: Incidence of abnormal vital sign measurements, Incidence of abnormal Clinical Laboratory Data and 9 more. Started Feb 2021; status: completed.
02
Drugs
risvodetinib
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04350177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04350177.